{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-037384","form_type":"8-K","ticker":"DNA","cik":"0001830214","company_name":"Ginkgo Bioworks Holdings, Inc.","filed_at":"2024-08-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.768489+00:00","generated_at":"2026-05-31T09:05:25.500236+00:00","sec_items":["5.07","8.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Ginkgo Bioworks shareholders approve reverse split; board sets 1:40 ratio","bullets":["Reverse stock split approved by shareholders (4.7B votes for); board set ratio at 1:40.","Split effective Aug 19; shares trade split-adjusted Aug 20 under symbol DNA.","Every 40 shares of Common Stock combined into 1; fractional shares paid in cash.","Warrants adjusted: exercise price $460/share (or $11.50 per warrant); 40 warrants per share."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-037384","json":"https://secwatch.observer/filing/0001628280-24-037384.json","markdown":"https://secwatch.observer/filing/0001628280-24-037384.md","text":"https://secwatch.observer/filing/0001628280-24-037384.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1830214/000162828024037384/0001628280-24-037384-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1830214/000162828024037384/dna-20240814.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T09:05:25.500236+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}